Press Releases
- Active Biotech Interim Report Q2 2024
- Active Biotech provides update on the clinical phase Ib/IIa study with tasquinimod in relapsed refractory multiple myeloma
- Active Biotech enters agreement for a clinical study of tasquinimod in myelofibrosis
- Number of shares and votes in Active Biotech
- Clinical activity and safety of naptumomab and docetaxel to be presented at ASCO 2024